NYSE
232.54USD
-0.11 (-0.05%)
We have scored 54 news catalysts on Cardinal Health, Inc. (CAH) over the past 12 months. The biggest single-day move next to one of them came Feb 5, 2026, when CAH closed +9.8%: “Nasdaq 100 and S&P500: Tech Stocks Slide as AI Spending Hits US Stocks Today”. Coverage across the window leans positive (average ticker sentiment +0.53). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
54.5B
P/E
—
EPS
—
Beta
0.52
52W range
145.87-258.3
Day range
232.09–234.75
Open
233.07
Prev close
232.65
Volume
1.2M
Avg volume
2.2M
Dividend
2.05
IPO
1983-08-04
Analysts publish price targets on CAH, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $250 to $292
as of 2026-09-04
The market is 9% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cardinal Health, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CAH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
The price sits at the very bottom of the published model range, endorsing the lowest targets and explicitly rejecting the 17% upside priced into the sole bull case.
What the disagreement turns on
Does the Pharmaceutical and Specialty Solutions segment have the structural margin power to sustain high-single-digit or greater profit growth despite the guided revenue deceleration, and our wired data can only measure the top-line unit volumes, not the pricing or margins that would settle this.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $249 on 2026-09-04 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
